Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma

  • Dominik Bogen
    Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
  • Jun S. Wei
    Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
  • David O. Azorsa
    Clinical Translational Research Division, Translational Genomics Research Institute (TGen), Scottsdale, AZ, USA
  • Pinar Ormanoglu
    Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
  • Eugen Buehler
    Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
  • Rajarshi Guha
    Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
  • Jonathan M. Keller
    Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
  • Lesley A. Mathews Griner
    Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
  • Marc Ferrer
    Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
  • Young K. Song
    Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
  • Hongling Liao
    Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
  • Arnulfo Mendoza
    Tumor and Metastasis Biology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
  • Berkley E. Gryder
    Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
  • Sivasish Sindri
    Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
  • Jianbin He
    Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
  • Xinyu Wen
    Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
  • Shile Zhang
    Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
  • John F. Shern
    Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
  • Marielle E. Yohe
    Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
  • Sabine Taschner-Mandl
    Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria
  • Jason M. Shohet
    Texas Children's Cancer Center and Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
  • Craig J. Thomas
    Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
  • Scott E. Martin
    Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
  • Peter F. Ambros
    Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria
  • Javed Khan
    Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

収録刊行物

  • Oncotarget

    Oncotarget 6 (34), 35247-35262, 2015-10-21

    Impact Journals, LLC

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ